The following serious adverse reactions are described elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data in Warnings and Precautions reflect exposure to topotecan from 8 trials in which 879 patients with small cell lung cancer (SCLC) and other solid tumors received topotecan 1.5 mg/m2 by intravenous infusion daily for 5 consecutive days, starting on Day 1 of a 21-day cycle.
Small Cell Lung Cancer (SCLC)
The safety of topotecan was evaluated in randomized, comparative trial in patients with recurrent or progressive SCLC (Study 090) [see Clinical Studies (14.1)]. Table 1 shows the Grade 3 or 4 hematologic and non-hematologic adverse reactions in patients with SCLC.
| Adverse Reactions | Topotecan (n = 107) | CAV* (n = 104) |
|---|---|---|
| Grade 3–4 (%) | Grade 3–4 (%) | |
| Hematologic | ||
| Grade 4 neutropenia (< 500/mm3) | 70 | 72 |
| Grade 3 or 4 anemia (Hgb < 8 g/dL) | 42 | 20 |
| Grade 4 thrombocytopenia (< 25,000/mm3) | 29 | 5 |
| Febrile neutropenia | 28 | 26 |
| Non-Hematologic | ||
| Respiratory, thoracic, and mediastinal | ||
| Dyspnea | 9 | 14 |
| Pneumonia | 8 | 6 |
| General and administrative site conditions | ||
| Asthenia | 9 | 7 |
| Fatigue | 6 | 10 |
| Pain† | 5 | 7 |
| Gastrointestinal | ||
| Nausea | 8 | 6 |
| Abdominal pain | 6 | 4 |
| Infections | ||
| Sepsis‡ | 5 | 5 |
The following reactions have been identified during postapproval use of topotecan. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following serious adverse reactions are described elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data in Warnings and Precautions reflect exposure to topotecan from 8 trials in which 879 patients with small cell lung cancer (SCLC) and other solid tumors received topotecan 1.5 mg/m2 by intravenous infusion daily for 5 consecutive days, starting on Day 1 of a 21-day cycle.
Small Cell Lung Cancer (SCLC)
The safety of topotecan was evaluated in randomized, comparative trial in patients with recurrent or progressive SCLC (Study 090) [see Clinical Studies (14.1)]. Table 1 shows the Grade 3 or 4 hematologic and non-hematologic adverse reactions in patients with SCLC.
| Adverse Reactions | Topotecan (n = 107) | CAV* (n = 104) |
|---|---|---|
| Grade 3–4 (%) | Grade 3–4 (%) | |
| Hematologic | ||
| Grade 4 neutropenia (< 500/mm3) | 70 | 72 |
| Grade 3 or 4 anemia (Hgb < 8 g/dL) | 42 | 20 |
| Grade 4 thrombocytopenia (< 25,000/mm3) | 29 | 5 |
| Febrile neutropenia | 28 | 26 |
| Non-Hematologic | ||
| Respiratory, thoracic, and mediastinal | ||
| Dyspnea | 9 | 14 |
| Pneumonia | 8 | 6 |
| General and administrative site conditions | ||
| Asthenia | 9 | 7 |
| Fatigue | 6 | 10 |
| Pain† | 5 | 7 |
| Gastrointestinal | ||
| Nausea | 8 | 6 |
| Abdominal pain | 6 | 4 |
| Infections | ||
| Sepsis‡ | 5 | 5 |
The following reactions have been identified during postapproval use of topotecan. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.